Assessment of Objective and Subjective Cognitive Function in Patients With Treatment-Resistant Depression Undergoing Repeated Ketamine Infusions

DOI PDF PDF 被引用文献1件
  • Jennifer L Phillips
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Amanda Van Geel
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Patricia Burhunduli
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Dominique Vasudev
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Lisa A Batten
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Sandhaya Norris
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Jeanne Talbot
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Abigail Ortiz
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Olabisi Owoeye
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada
  • Pierre Blier
    University of Ottawa Institute of Mental Health Research at The Royal , Ottawa, Ontario , Canada

抄録

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Subanesthetic ketamine infusions can elicit rapid and sustained antidepressant effects, yet the potential cognitive impact of ketamine has not been thoroughly examined. This study measured changes in objective and subjective cognitive function following repeated ketamine treatment.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Thirty-eight patients with treatment-resistant depression were administered cognitive assessments before and after undergoing 7 i.v. ketamine infusions (0.5 mg/kg over 40 minutes) within a clinical trial examining the efficacy of single and repeated administrations. Depression severity and perceived concentration were evaluated with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptoms Self-Report.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Twenty-three participants (60.5%) responded after repeated infusions (≥50% decrease in MADRS total scores). We measured significant improvements in several cognitive domains, including attention, working memory, verbal, and visuospatial memory (effect sizes ranging from Cohen d = 0.37–0.79). Cognitive changes were attributed to reduction in depressive symptoms except for improvement in verbal memory, which remained significant after adjustment for change in MADRS total score (P = .029, η p2 = 0.13). Only responders reported improvement in subjective cognitive function with repeated ketamine administration (MADRS item 6, P &lt; .001, d = 2.00; Quick Inventory of Depressive Symptoms Self-Report item 10, P &lt; .001, d = 1.36).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>A short course of repeated ketamine infusions did not impair neurocognitive function in patients with treatment-resistant depression. Further research is required to understand the potential mediating role of response and remission on improved cognitive function accompanying ketamine treatment as well as to examine longer-term safety outcomes. ClinicalTrials.gov identifier NCT01945047</jats:p> </jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ